roiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 2004;150:363-9. 4 To the Editor: Lectin-like oxidized LDL receptor-1 (LOX-1) is prominently expressed in atherosclerotic plaques (1, 2 ). LOX-1 expressed on the cell surface is proteolytically cleaved at its membraneproximal extracellular domain (ECD) and released in soluble form (sLOX-1) (2, 3 ). Serum sLOX-1 is increased at an earlier stage of acute coronary syndrome (ACS) than are other cardiac makers, such as creatine kinase-MB fraction, troponin T, and high-sensitivity C-reactive protein (4 ). We describe the development of an ELISA for sLOX-1.
ELISA for Soluble Form of Lectin-Like Oxidized LDL Receptor-1, A Novel Marker of Acute Coronary Syndrome
To the Editor: Lectin-like oxidized LDL receptor-1 (LOX-1) is prominently expressed in atherosclerotic plaques (1, 2 ) . LOX-1 expressed on the cell surface is proteolytically cleaved at its membraneproximal extracellular domain (ECD) and released in soluble form (sLOX-1) (2, 3 ) . Serum sLOX-1 is increased at an earlier stage of acute coronary syndrome (ACS) than are other cardiac makers, such as creatine kinase-MB fraction, troponin T, and high-sensitivity C-reactive protein (4 ) . We describe the development of an ELISA for sLOX-1.
The cleavage sites on human LOX-1 (hLOX-1) remain unknown. We tried to obtain human sLOX-1 (hsLOX-1) from cultures of CHO-K1 cells stably expressing hLOX-1 (3, 5) , but the amount of hsLOX-1 obtained was too small for ELISA development.
hsLOX-1 should be similar to the ECD of hLOX-1 (hLOX-1-ECD), considering a structure of bovine sLOX-1 (3 ). We produced recombinant hLOX-1-ECD [rhLOX-1-ECD; hLOX-1 (84 -273)] in Escherichia coli and purified it as described previously (5 ); we then used the soluble fraction of rhLOX-1-ECD instead of hsLOX-1 as the assay calibrator and immunogen. We estimated the amount of rhLOX-1-ECD by ultraviolet spectrophotometry, using the formula: E 280 nm 1% ϭ 10.0. To produce the K266 and K267 antisera, we immunized 2 female rabbits (KBL:JW; Kitayama Labs) with an emulsion of rhLOX-1-ECD solution in Freund's complete adjuvant [ϳ0.4 mg (0.5 mL) per dose]. Each rabbit received a dose once every 3 weeks for a total of 6 doses.
We used K266 IgG as the immobilized (capture) antibody and horseradish peroxidase (HRP)-labeled K267 FabЈ as the detection antibody. K267 FabЈ was prepared and labeled with HRP by use of succinimidyl 4-(N-maleimidomethyl)cyclohexane 1-carboxylate (Pierce), as described previously (6 ) . Absorbance ratios at 280 and 403 nm indicated a 1:1 molecular binding ratio of HRP to K267 FabЈ. We added the preservative Proclin 150 (final concentration, 1 mL/L; Supelco) to the HRP-labeled antibody, which was stored at Ϫ80°C.
To immobilize the K266 antibody, we added 100 L of K266 Calibrator samples (1-100 g/L rhLOX-1-ECD in commercially available normal human plasma; George King Biomedical) or unknown samples of human serum/plasma (10 L) were added to 100 L of assay buffer in duplicate microplate wells containing immobilized antibody. The microplates were then incubated for 2 h at room temperature and washed twice. The HRP-labeled antibody solution (100 L; diluted to ϳ900 g/L in the assay buffer) was then added to the microplate wells and incubated for 16 h at room temperature. We then washed the microplate wells twice and added the substrate solution (100 L) containing 3,3Ј,5,5Ј-tetramethylbenzidine (TMBϩ; Dako). We allowed the enzyme reaction to take place for 30 min in the dark and then stopped the reaction with 0.5 mol/L sulfuric acid (100 L). The absorbance at 450 nm was measured by a plate reader (ARVOsx; Wallac/Perkin-Elmer).
We evaluated the effects of endogenous sLOX-1 by assaying 10-L samples of individual plasmas from 6 healthy volunteers and the commercially available plasma; the differences between the results were negligible. ELISA binding was not changed in plasma samples containing heparin, EDTA, or citrate, and we observed no differences between plasma and serum. , which may bind sLOX-1 in the calibrator solutions (10 g/L), had no effect (4 ) .
The ELISA calibration curve indicated a good response to rhLOX-1-ECD (1-100 g/L) as well as to hsLOX-1 (Fig. 1) , suggesting that this ELISA can measure natural forms of human sLOX-1. Intra-/interassay imprecision (as CV) was 2.0%-12%, and measured values were within Ϫ2.5% to ϩ7.0% of the expected values for the range 1-100 g/L. The limit of quantification was 1.0 g/L. Plasma (serum) concentrations Ͼ0.5 g/L were detectable; however, de-tection of concentrations Ͻ1 g/L was unreliable.
rhLOX-1-ECD in plasma at concentrations of 1.79, 8.64, and 41.4 g/L was stable at Ϫ40°C for 14 weeks and during 3 freeze-thaw cycles.
Our results indicate that the proposed ELISA measured sLOX-1 specifically and sensitively in human serum/plasma and can be used as a diagnostic test for ACS at the earliest stage.
